Allarity Therapeutics, Inc. (ALLR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0167445008
Allarity Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 320,000.00 USD |
| Operating income | -12.61 m USD |
| EBIT | -11.85 m USD |
| Net income | -11.23 m USD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
More stocks
- aTYR PHARMA INC (ATYR)
- Acumen Pharmaceuticals, Inc. (ABOS)
- ASHFORD HOSPITALITY TRUST INC (AHT)
- TRANSUITE.ORG INC. (TRSO)
- SBI Investment KOREA Co. Ltd (019550.KQ)
- Longduoduo Co Ltd (LDDD)
- Jasper Therapeutics, Inc. (JSPR)
- Cytosorbents Corp (CTSO)
- Pluri Inc. (PLUR)
- Bridger Aerospace Group Holdings, Inc. (BAER)
- Investcorp Credit Management BDC, Inc. (ICMB)
- Security Midwest Bancorp, Inc. (SBMW)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.